02063nas a2200349   4500000000100000008004100001260001300042653001000055653001200065653003300077653003000110653001100140653001100151653001300162653001200175653000900187653001500196653001300211100001300224700001700237700001500254700001400269700001500283700001500298700001100313245010800324856004100432300001100473490000700484520120800491022001401699       1989                            d  c1989 Jun10aAdult10aDapsone10aDrug Administration Schedule10aDrug Therapy, Combination10aFemale10aHumans10aLepromin10aleprosy10aMale10aRecurrence10aRifampin1 aKatoch K1 aRamanathan U1 aNatrajan M1 aBagga A K1 aBhatia A S1 aSaxena R K1 aRamu G00aRelapses in paucibacillary patients after treatment with three short-term regimens containing rifampin.  uhttp://ila.ilsl.br/pdfs/v57n2a02.pdf  a458-640 v573 a<p>Three multidrug regimens all containing rifampin and dapsone have been tried for the treatment of 278 cases of paucibacillary leprosy. Regimen I was the one recommended by the WHO Study Group. Regimen II was the same as Regimen I with depsone alone continued for a further 6 months. Regimen III was the same as Regimen II but rifampin was given daily for the first 7 days. The patients were comparable with regard to disease classification, lepromin status, bacteriological status, and number of lesions. As reported earlier, the disease inactivity rates by 1 year of treatment were much greater with Regimens II and III than with Regimen I (94% and 97% vs 76%). Early reaction was seen in 6% of those in Regimen III and in none in Regimens I and II. Late reaction was observed in 9% of those in Regimen I and none in Regimens II and III. During 3 1/2 years of follow up, 13% of the cases in Regimen I, 1% in Regimen II, and 2% in Regimen III relapsed. Since the patients in the three regimens were otherwise comparable, it is concluded that the high inactivity rate, low relapse rate (1%-2%), and no early or late reaction as observed in Regimen II patients were because of adequate treatment.</p>
  a0148-916X